Tags

Type your tag names separated by a space and hit enter

Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Hepatobiliary Pancreat Dis Int. 2004 Aug; 3(3):464-8.HP

Abstract

BACKGROUND

Although a variety of tumor markers are available for diagnosis of pancreatic cancer, their sensitivity and specificity have not yet been ideal. The aims of this study was to detect a panel of serum tumor markers and to evaluate their significance in the diagnosis and prognosis of pancreatic cancer patients.

METHODS

Eight serum tumor markers including AFP, CEA, CA-50, CA72-4, CA-125, CA153, CA19-9 and CA242 were detected in 129 patients with pancreatic cancer by using chemiluminescence immunoassay, immunofluorescence assay and immunoradiometric assay, respectively. The levels of these markers were compared in 99 patients with non-pancreatic malignant tumor, 63 patients with other benign diseases, and 27 patients with pancreatic cancer after pancreatectomy.

RESULTS

Among the 8 tumor markers, CA19-9, CA242, CA-50, and CA72-4 were more sensitive in the diagnosis of pancreatic cancer. Parallel combined testing could increase the diagnostic sensitivity to 89.2%, and serial combined examination could increase the diagnostic specificity to 92.3%. The serum tumor markers levels were decreased significantly after radical tumor resection.

CONCLUSIONS

Serum CA19-9, CA242, CA-50, and CA72-4 are the preferred tumor markers to be used in the diagnosis and follow-up of operated cases of pancreatic cancer. Testing of a panel of multiple serum tumor markers may increase the sensitivity and specificity in the diagnosis of pancreatic cancer.

Authors+Show Affiliations

Clinical Medical Laboratory, Zhejiang Provincial People's Hospital, Hangzhou 310014, China. Jiangxiaoting2002@hotmail.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15313690

Citation

Jiang, Xiao-Ting, et al. "Detection of Serum Tumor Markers in the Diagnosis and Treatment of Patients With Pancreatic Cancer." Hepatobiliary & Pancreatic Diseases International : HBPD INT, vol. 3, no. 3, 2004, pp. 464-8.
Jiang XT, Tao HQ, Zou SC. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. HBPD INT. 2004;3(3):464-8.
Jiang, X. T., Tao, H. Q., & Zou, S. C. (2004). Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Hepatobiliary & Pancreatic Diseases International : HBPD INT, 3(3), 464-8.
Jiang XT, Tao HQ, Zou SC. Detection of Serum Tumor Markers in the Diagnosis and Treatment of Patients With Pancreatic Cancer. HBPD INT. 2004;3(3):464-8. PubMed PMID: 15313690.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. AU - Jiang,Xiao-Ting, AU - Tao,Hou-Quan, AU - Zou,Shou-Chun, PY - 2004/8/18/pubmed PY - 2004/11/13/medline PY - 2004/8/18/entrez SP - 464 EP - 8 JF - Hepatobiliary & pancreatic diseases international : HBPD INT JO - HBPD INT VL - 3 IS - 3 N2 - BACKGROUND: Although a variety of tumor markers are available for diagnosis of pancreatic cancer, their sensitivity and specificity have not yet been ideal. The aims of this study was to detect a panel of serum tumor markers and to evaluate their significance in the diagnosis and prognosis of pancreatic cancer patients. METHODS: Eight serum tumor markers including AFP, CEA, CA-50, CA72-4, CA-125, CA153, CA19-9 and CA242 were detected in 129 patients with pancreatic cancer by using chemiluminescence immunoassay, immunofluorescence assay and immunoradiometric assay, respectively. The levels of these markers were compared in 99 patients with non-pancreatic malignant tumor, 63 patients with other benign diseases, and 27 patients with pancreatic cancer after pancreatectomy. RESULTS: Among the 8 tumor markers, CA19-9, CA242, CA-50, and CA72-4 were more sensitive in the diagnosis of pancreatic cancer. Parallel combined testing could increase the diagnostic sensitivity to 89.2%, and serial combined examination could increase the diagnostic specificity to 92.3%. The serum tumor markers levels were decreased significantly after radical tumor resection. CONCLUSIONS: Serum CA19-9, CA242, CA-50, and CA72-4 are the preferred tumor markers to be used in the diagnosis and follow-up of operated cases of pancreatic cancer. Testing of a panel of multiple serum tumor markers may increase the sensitivity and specificity in the diagnosis of pancreatic cancer. SN - 1499-3872 UR - https://www.unboundmedicine.com/medline/citation/15313690/Detection_of_serum_tumor_markers_in_the_diagnosis_and_treatment_of_patients_with_pancreatic_cancer_ L2 - http://www.diseaseinfosearch.org/result/5551 DB - PRIME DP - Unbound Medicine ER -